Lombard Odier Asset Management (Switzerland) Sa Neurocrine Biosciences Inc Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $357,053 - $466,737	-3,794 Reduced 2.76%	133,656 $13.5 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $6.58 Million - $7.83 Million	-61,642 Reduced 30.96%	137,450 $16.4 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $1.46 Million - $1.71 Million	-15,838 Reduced 7.37%	199,092 $21.1 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1.85 Million - $2.44 Million	24,362 Added 12.78%	214,930 $21 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $5.22 Million - $6.84 Million	-72,097 Reduced 27.45%	190,568 $17.9 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $1.81 Million - $2.41 Million	22,682 Added 9.45%	262,665 $22.4 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $2 Million - $2.3 Million	23,192 Added 10.7%	239,983 $23 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $5.99 Million - $6.84 Million	66,927 Added 44.66%	216,791 $21.1 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $13.1 Million - $17.9 Million	149,864 New	149,864 $14.6 Million

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$1.78 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.26 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$647 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$323 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$234 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account